Rockwell Medical Revenue and Competitors
Estimated Revenue & Valuation
- Rockwell Medical's estimated annual revenue is currently $37.7M per year.
- Rockwell Medical received $55.0M in venture funding in November 2014.
- Rockwell Medical's estimated revenue per employee is $251,250
- Rockwell Medical's total funding is $35M.
Employee Data
- Rockwell Medical has 150 Employees.
- Rockwell Medical grew their employee count by -9% last year.
Rockwell Medical's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP, Finance | Reveal Email/Phone |
2 | SVP, Finance | Reveal Email/Phone |
3 | SVP Sales and Marketing | Reveal Email/Phone |
4 | VP, Strategic Accounts | Reveal Email/Phone |
5 | VP Human Resources | Reveal Email/Phone |
6 | SVP, Finance and Chief Accounting Officer | Reveal Email/Phone |
7 | VP, Strategic Accounts | Reveal Email/Phone |
8 | SVP, Corporate & Business Development | Reveal Email/Phone |
9 | SVP, Chief Corporate Affairs Officer | Reveal Email/Phone |
10 | Senior Director, Clinical Operations | Reveal Email/Phone |
Rockwell Medical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Rockwell Medical?
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell's new innovative therapy Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information. Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, with three manufacturing/distribution facilities located in the U.S. Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell's exclusive renal drug therapies support disease management initiatives to improve quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing costs and improving patient convenience.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals$35M
Total Funding
150
Number of Employees
$37.7M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rockwell Medical News
Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and...
Rockwell Medical, Inc is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency,...
In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the...
- 2020 revenue of $62.2 million - - Ended the year with $58.7 million in cash, cash equivalents and investments - - Conference call and webcast on Wednesday, March 31st at 4:30 p.m. ET - WIXOM, Mich., March 31, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutica ...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints In May, we wrote about the Wixom, MI-based company Rockwell Medical, which disrupted the dialysis industry by being the first to develop, patent, and bring to market a dry acid mixing system for hemodialysis concentrate. Last wee ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $60.2M | 155 | 5% | N/A |
#2 | $37.7M | 167 | 4% | N/A |
#3 | $59.3M | 168 | 17% | N/A |
#4 | $68.6M | 189 | 29% | N/A |
#5 | $67.4M | 201 | 7% | N/A |
Rockwell Medical Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2005-03-31 | $2.8M | Undisclosed | Standard Federal Bank | Article |
2005-04-14 | $6.5M | Undisclosed | Article | |
2012-02-13 | $17.5M | Undisclosed | Stifel Nicolaus Weisel | Article |
2013-03-27 | $12.9M | Undisclosed | Chardan Capital Markets LLC | Article |
2013-05-16 | $35.0M | Undisclosed | Article | |
2013-06-19 | $20.0M | Undisclosed | Hercules Technology Growth Cap | Article |
2014-11-19 | $55.0M | Undisclosed | BofA Merrill Lynch | Article |